# Conservative Treatments of Retinoblastoma

> **NCT02866136** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Institut Curie** · enrollment: 133 (estimated)

## Conditions studied

- Retinoblastoma
- Children
- Retinal Neoplasm

## Interventions

- **DRUG:** VP16, carboplatin
- **DRUG:** Melphalan
- **DRUG:** VP16, carboplatin, vincristin
- **DRUG:** Carboplatin + laser day 1 (chemothermotherapy)
- **DEVICE:** Laser (local treatment)
- **DEVICE:** cryoapplication (local treatment)
- **RADIATION:** I125 radioactive plaques (local treatment)
- **DRUG:** intravitreal Melphalan (local treatment)

## Key facts

- **NCT ID:** NCT02866136
- **Lead sponsor:** Institut Curie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-02
- **Primary completion:** 2023-01
- **Final completion:** 2035-09
- **Target enrollment:** 133 (ESTIMATED)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02866136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02866136, "Conservative Treatments of Retinoblastoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02866136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*